A morphine plasma concentration/respiratory rate relationship has been described for both adults and children although that of its metabolite, morphine-6-glucuronide, remains uncertain. We describe this relationship in a child with end-stage renal failure who received repeat morphine administration over two days. An E MAX model for additive morphine and morphine-6-glucuronide respiratory effects described respiratory rate better than models describing either alone. Failure to clear morphine-6-glucuronide renally led to respiratory depression episodes occurring later than those predicted by modelling morphine levels only. These findings support the use of alternative analgesics (e.g. fentanyl) that are cleared by non-renal pathways and have no active metabolites in patients with end-stage renal disease.
Morphine is a commonly used analgesic in both adult and paediatric practice, but it is known to cause dose-related respiratory depression. A direct relationship between morphine concentration and this effect has been established. Morphine plasma concentrations above 20 ng.ml -1 are associated with hypercarbia and depress carbon dioxide response in children (2-570 days postnatal age) following cardiac surgery 1 . Respiratory depression persists after ceasing morphine infusions; morphine concentrations over 15 ng.ml -1 are associated with hypercarbia in 46% of children, while concentrations less than 15 ng.ml -1 are associated with hypercarbia in 13% 1 . Morphine respiratory effects may be confounded by those of its active metabolites. Around 60% of morphine is converted to morphine-3-glucuronide, and a further 6-10% to morphine-6-glucuronide (M6G). M6G has analgesic and respiratory depressant effects and is predominantly cleared by the kidneys. Consequently, in patients with poor renal function, morphine metabolites accumulate due to little or no clearance, and metabolite effects may compound with those of the parent drug. Modelling the effect of morphine on respiratory rate may be improved by including M6G effects. We report a simple modelling simulation for morphine and M6G effects on respiratory rate in a child with severe renal dysfunction.
CASE REPORT
Written consent to model and publish these data was given by the patient and his parents at the time of treatment (1997) and again prior to publication of this case report (2012). A 12-year-old male child (27 kg) with end-stage renal failure, hyperparathyroidism, hypertension and congestive heart failure was scheduled for parathyroid resection. Preoperative medications included nifedipine, labetalol and captopril. Surgery and post-anaesthetic recovery were uneventful and he was transferred to intensive care for electrolyte monitoring and analgesic control. A nitroprusside infusion was used to control hypertension perioperatively, and captopril and labetalol were reinstituted after surgery. Intravenous morphine delivered by a patient-controlled analgesia device was prescribed for postoperative pain control. Patientcontrolled analgesia was restricted to morphine 0.5 mg as a bolus with a five-minute lockout period before subsequent dosing. Hourly morphine dose was recorded directly from the patient-controlled analgesia pump for 50 postoperative hours, and respiratory rate was recorded hourly by nursing staff. The child was receiving regular haemodialysis and this treatment was scheduled postoperatively on day two but was delayed until 45 hours postoperatively because of heavy weekend service commitments. Oxygen 4 l.minute -1 was delivered by a Hudson mask postoperatively and no desaturation was observed over the study period.
Modelling methods
Predicted plasma concentrations of morphine and M6G were estimated from morphine doses using a published model of morphine pharmacokinetics in children 2 . Parameter estimates were for a one compartment, first order elimination model with an estimated morphine volume of distribution (V) of 136 l.70 kg -1 , morphine-3-glucuronide formation clearance 64.3 l.hour -1 .70 kg -1 and V 23 l.70 kg -1 , M6G formation clearance 3.63 l.hour -1 .70 kg -1 and V 30 l.70 kg -1 , and morphine clearance by other routes 3.12 l.hour -1 .70 kg -1 2 . As this child had severe renal dysfunction and was anuric, metabolite clearances were fixed at 0.001 l.hour -1 .70 kg -1 until dialysis began, reflecting renally dependent clearance pathways for these metabolites.
A delayed effect compartment model was used to describe morphine and M6G concentrations causing respiratory depression. The temporal relationship between predicted concentrations in plasma and effect compartments was described by an equilibration rate constant (Keo), derived from an estimated equilibration half-time (T ½ keo):
The relationship between estimated morphine effect site concentrations and observed respiratory rate was described using the Hill equation: E 0 is the baseline respiratory rate, E MAX is the maximal reduction in respiratory rate (the lowest possible respiratory rate was assumed as zero), CONC is the concentration of drug, EC 50 is the concentration of drug producing 50% of E MAX and Hill is a parameter describing the sigmoidal curve shape.
This model was again used to describe the effect of M6G alone using a Keo for M6G transfer to the M6G effect compartment. Finally, a model describing combined added effects of morphine and M6G was tested in which total effect on respiratory rate was calculated as E M + E M6G (E M is the morphine effect and E M6G is the M6G effect as described using Equation 2). Data were insufficient to adequately estimate the nature of the interaction, and we assumed an
Keo additive interaction as our null hypothesis (and as the simplest model of combined drug effect). Residual unidentified variability was described using an additive error model for each observation prediction (Err ADD ). Parameters and residual variance were estimated using the first order conditional interaction estimate method with ADVAN4 TRANS4 of NONMEM VI (Icon Development Solutions, Ellicott, MD, USA). Convergence criterion was three significant digits.
The fit of each model to the data was sought using NONMEM's objective function (OBJ) and visual examination for plots of observed versus predicted respiratory rates. Models were nested and an improvement in the OBJ was referred to the chisquare distribution to assess significance, e.g. a change of 3.84 is significant at α=0.05. A visual predictive check 3 , a modelling tool that estimates prediction intervals and graphically superimposes these on observed respiratory rates, was used to evaluate how well the model predicted the distribution of observed respiratory rates.
The combined effect model for morphine with M6G was better than those using either morphine (∆OBJ 47.694) or M6G alone (∆OBJ 4.809) ( Figure 1 ). Baseline respiratory rate was 20.7 breaths.minute -1 and E MAX assumed as zero. The EC 50 for both morphine and M6G was 16.9 ng.ml -1 ; individual parameters did not improve the OBJ. Similarly morphine and M6G shared a Hill parameter of 2.35, as individual parameters did not significantly improve our model. The T ½ keo for morphine was 16 minutes, Respiratory rate, breaths.minute -1 Figure 1 : Visual predictive check for the combined morphine and M6G effect model. The plot shows median and 90% intervals (solid and dashed lines respectively). Prediction percentiles (10, 50 and 90%) for observations (lines with symbols) and predictions (lines) with 95% confidence intervals for prediction percentiles (grey shaded areas).
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DISCUSSION
The observations from this child are consistent with an effect of both morphine and M6G on respiratory effect. M6G levels accumulate in children with renal failure but are cleared by dialysis. Observations in this child allowed assessment of M6G effects on respiratory rate. Peak respiratory depression has been observed to occur considerably later than expected from peaks in morphine concentrations 4 , and it is likely that this reflects the process of morphine metabolism to its active metabolite, M6G, and subsequent movement of M6G from plasma to an effect site where it acts to depress respiration.
A model of morphine effect alone inadequately described initial changes in respiration and late respiratory depression at around 35 hours in this child. A model using only M6G better described late respiratory depression ( Figure 2 ) but failed to track observed respiratory rates in the first ten hours. A model describing additive effects of both morphine and M6G improved the fit for both early and late respiratory rates. An additive effect was assumed as animal data suggest that morphine and M6G act via distinct μ receptor pathways and that an additive relationship exists between morphine and M6G for analgesic effects 5, 6 . The interaction for respiratory depression is unknown.
Morphine shares similar pharmacodynamics for respiratory depression and analgesia 7 . Our estimate for the morphine T ½ keo of 16 minutes is the same as that reported for analgesia 8, 9 , and our M6G T ½ keo of 6.7 hours is within the four to eight hour range reported for delayed M6G analgesic effect 9 . We were unable to distinguish between the EC 50 for the parent and its metabolite, although the EC 50 for morphine of 16.9 ng.ml -1 is consistent with clinical observations for both analgesic concentrations (10-20 ng.ml -1 ) 10-12 and respiratory depression (hypercapnoea in 46% children with concentration >15 ng.ml -1 ) 1 . Others have also reported that hypercapnoeic ventilator responses for both parent and metabolite are similar (EC 50 10-18 ng.ml -1 ) 7, 9, 13 . The response curve steepness (represented by the Hill parameter) for morphine and M6G were indistinguishable; this has also been noted by others examining the hypercapnoeic ventilator 9 and pupillary responses to morphine and M6G 14 .
We used a population model for pharmacokinetic predictions and these may not be typical for the index child 15 . Respiratory changes due to external stimulation are not accounted for (e.g. acute pain from intravenous cannula insertion at approximately 31 hours). The model cannot estimate between subject variability. Despite these limitations, this simulation demonstrates the importance of considering active metabolite effects on respiratory depression when using morphine in postoperative settings over longer durations. This case report illustrates the dangers of morphine use in children with end-stage renal failure and supports the use of alternative analgesics (e.g. fentanyl) cleared by nonrenal pathways and without active metabolites in patients with impaired renal function.
